Actinium Launches Iomab-ACT Program Offering Its Targeted, Chemo-Free, Lymphodepletion Technology as a Universal Solution to CAR-T Product Developers Oct 1, 2018
Actinium Pharmaceuticals to Host Webinar Today Introducing Next Generation Targeted Lymphodepletion Technology for CAR-T Sep 26, 2018
Actinium Pharmaceuticals to Participate in the Oppenheimer & Co. Fall Summit Focused on Specialty Pharma and Rare Disease Sep 20, 2018
Actinium Pharmaceuticals to Host Webinar Showcasing New Pipeline Initiative Focused on the CAR-T Space Sep 18, 2018
Actinium Appoints Robert N. Daly, Ph.D. to Newly Created Role of Vice President, Head of Clinical Operations Sep 6, 2018
Actinium Pharmaceuticals to Present at Upcoming Investor Conferences and Participate in Featured Panel Discussions Sep 4, 2018
Actinium to Provide Update on Pivotal Phase 3 SIERRA Trial Following Positive Data Monitoring Committee Meeting Aug 14, 2018
Actinium Forms Nuclear Medicine Focused Advisory Board to Facilitate Pipeline Clinical Development and Iomab-B Commercial Planning Jul 17, 2018
Actinium to Host Webcast on July 10, 2018 to Discuss Actimab-A MRD clinical trial for Minimal Residual Disease in Postremission AML Patients Jul 9, 2018
Actinium Announces New Clinical Trial to Study Effect of Actimab-A on Minimal Residual Disease in Postremission AML Patients Jun 28, 2018
